佐力药业：收购多微注射液资产组 完善“全龄覆盖”战略

Core Viewpoint - Zhejiang Zuoli Pharmaceutical Co., Ltd. announced the acquisition of an asset group related to various trace element injection solutions for a total price of RMB 35.6 million, which includes both marketed and in-development products [1] Group 1: Acquisition Details - The asset group includes marketed products "Trace Element Injection (I)" and "Trace Element Injection (II)", as well as the in-development "Trace Element Injection (III)" along with related R&D production technical data, marketing licenses, trademarks, and patents [1] - The trace element injections are a primary source of trace elements for parenteral nutrition, particularly suitable for children and critically ill patients [1] Group 2: Market Potential - The overall market size for trace element injections is projected to reach approximately RMB 1.8 billion by 2024, with continued growth expected, especially in pediatric nutrition support and adult critical care nutrition [1] - The market is anticipated to expand further with the introduction of new products, deeper market education, and increased patient acceptance [1] Group 3: Strategic Importance - The acquisition is a significant step in completing the company's "full-age coverage" strategy, filling a gap in the pediatric treatment area and extending the product line to key scenarios in children's and elderly nutrition support [2] - The company aims to build a comprehensive health product and service chain that spans children, adults, and the elderly, aligning with national health development strategies [2] Group 4: Competitive Advantage - The company plans to leverage its existing marketing system and the advantages of the acquired asset group to drive growth, benefiting from established market foundations and procurement qualifications [3] - The trace element injections have a solid market presence, and the company's experience in clinical promotion across multiple departments will facilitate collaborative development with the new product line [3] - The asset group is expected to enhance the company's profitability and market competitiveness, with a projected net profit of RMB 45.79 million for the first nine months of 2025 [3]